Could Biomarkers Direct Therapy for the Septic...
Transcript of Could Biomarkers Direct Therapy for the Septic...
JPET #230797
1
Could Biomarkers Direct Therapy for the Septic Patient?
Clark R. Sims, Trung C. Nguyen, and Philip R. Mayeux
Department of Pharmacology and Toxicology, University of Arkansas for Medical
Sciences, Little Rock, Arkansas (C.R.S., P.R.M.), and Department of Pediatrics, Section
of Critical Care Medicine, Baylor College of Medicine/Texas Children’s Hospital,
Houston, Texas (T.C.N)
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
2
Running Title: (60 characters): Biomarker-Directed Therapy for the Septic Patient?
Corresponding Author:
Philip R. Mayeux, PhD
4301 West Markham Street, #611
Little Rock, AR 72205
501-686-8895
FAX: 501-686-5521
Number of text pages: 23
Number of tables: 0
Number of figures: 2
Number of references: 196
Number of words in Abstract: 190
Number of words in Introduction: 981
Number of words in Discussion: N/A
Section Assignment: Minireviews
Abbreviations: ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13; Ang, angiopoietin; CARS, compensatory anti-inflammatory
response syndrome; cfu, colony forming units; CLP, cecal ligation and puncture; CRP,
C-reactive protein; DAMPs, damage-associated molecular patterns; DIC,
disseminated intravascular coagulation; EEG, electroencephalography; GM-CSF,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
3
granulocyte macrophage colony-stimulating factor; HLA-DR, human leukocyte antigen
- antigen D related; ICAM-1, intercellular adhesion molecule 1; ICU, intensive care
unit; IL, interleukin; KIM-1, kidney injury molecule 1; LPS, lipopolysaccharide; MMP-8,
matrix metalloproteinase-8; MODS, multiple organ dysfunction syndrome; MRI,
magnetic resonance imaging; NAG, N-acetyl-β-(D)-glucosaminidase; NGAL,
neutrophil gelatinase-associated lipocalin; NIRS, near-infrared spectroscopy; PAMPs,
pathogen-associated molecular patterns; PCT, procalcitonin; PD-1, programmed cell
death 1; S1P, sphingosine-1-phosphate; SIRS, systemic inflammatory response
syndrome; TLR4, toll-like receptor 4; TNF-α, tumor necrosis factor α; VCAM-1,
vascular cell adhesion molecule 1; VWF, von Willebrand factor
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
4
Abstract
Sepsis is a serious medical condition caused by a severe systemic inflammatory
response to a bacterial, fungal, or viral infection that most commonly affects neonates
and the elderly. Advances in understanding the pathophysiology of sepsis have resulted
in guidelines for care that have helped reduce the risk of dying from sepsis for both
children and older adults. Still, over the past three decades, a large number of clinical
trials have been undertaken to evaluate pharmacological agents for sepsis.
Unfortunately, all of these trials have failed, with the use of some agents even shown to
be harmful. One key issue in these trials was the heterogeneity of the patient population
that participated. What has emerged is the need to target therapeutic interventions to
the specific patient’s underlying pathophysiological processes, rather than looking for a
universal therapy that would be effective in a “typical” septic patient who does not exist.
This review supports the concept that identification of the right biomarkers that can
direct therapy and provide timely feedback on its effectiveness will enable critical care
physicians to decrease mortality of patients with sepsis and improve the quality of life of
survivors.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
5
Introduction
Sepsis is a serious medical condition caused by a severe systemic inflammatory
response to a bacterial, fungal, or viral infection (Martin, 2012; Dellinger et al., 2013). As
sepsis worsens, organ dysfunction (severe sepsis) or severe sepsis plus hypotension
(septic shock) can develop (Dellinger et al., 2013). Sepsis affects approximately
700,000 people annually in the U.S. alone (Chang et al., 2015). Over 25% of these
patients die before leaving the hospital, making sepsis the 9th leading cause of death
overall (Heron, 2015). In addition, relative to the total number of cases, sepsis is the
most costly medical condition, especially given that over 20% of sepsis survivors are
readmitted within 30 days and nearly 30% of these patients have recurrent sepsis (Torio
and Andrews, 2013; Chang et al., 2015). The estimated annual health care burden is
over $20 billion in the U.S. alone (Torio and Andrews, 2013).
While sepsis affects people of all ages, the most commonly affected populations
are neonates, due to an immature immune system and still developing organs, and the
elderly, due to chronic and comorbid conditions. In the U.S., sepsis is the 6th and 7th
leading cause of death in neonates and infants, respectively, and the 10th leading cause
of death in patients age 65 and older (Heron, 2015). Mortality rates for children with
septic shock range from 9% to 25% (Hartman et al., 2013; Weiss et al., 2015), and for
older adults mortality rates are as high as 45% (Daviaud et al., 2015). Although the
absolute number of deaths from sepsis is increasing due to increasing incidence (Martin,
2012; Gaieski et al., 2013), advances in the understanding of the pathophysiology of
sepsis have reduced the risk of dying from sepsis for both children (Kissoon et al., 2011;
Ruth et al., 2014) and older adults (Stevenson et al., 2014).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
6
The pathophysiology of sepsis is very complex and still poorly understood.
Initially, local activation of the innate immune response by pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)
results in a “cytokine storm” (Wang and Ma, 2008; Gustot, 2011; Laszlo et al., 2015). If
the inflammatory response becomes systemic it manifests as the systemic inflammatory
response syndrome (SIRS, (Conference, 1992)). Patients who survive the initial
hyperinflammatory state may progress to a hypoinflammatory state and develop the
compensatory anti-inflammatory response syndrome (CARS, (Bone, 1996; Ward et al.,
2008)), which increases the susceptibility to recurrence of the primary infection or a
secondary acquired infection. Disruption of the balance between these inflammatory
and anti-inflammatory responses in sepsis leads to multiple organ dysfunction
syndrome (MODS), which significantly increases mortality (Wang and Ma, 2008; Gustot,
2011; Boomer et al., 2014).
Mortality from sepsis has significantly decreased over the years because of early
recognition and resuscitation, as documented in the “Surviving Sepsis Campaign”
(Dellinger et al., 2013). Following recommendations from this document, current
therapies are mostly supportive care. Initial treatment includes broad-spectrum
antibiotics and then fluid resuscitation if necessary. As sepsis severity increases,
therapy may require administration of vasopressors, use of mechanical respiratory
support, and/or renal replacement therapy (Dellinger et al., 2013). Over the past three
decades, there have been over 60 large Phase II and III randomized, controlled clinical
trials of single pharmacological agents for sepsis, all of which have failed, with some
agents even found to be harmful (Fink and Warren, 2014). Reflecting on these failed
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
7
trials, many leaders in the field believe that the heterogeneity of the patient population
that participated in these trials is a key issue (Cohen et al., 2015). To address this issue,
various critical care societies are currently revising the definition of the sepsis syndrome
to refine the inclusion criteria for participants in future sepsis trials. One common theme
is surfacing: infection plus organ dysfunction should be considered as inclusion criteria
rather than just the current two or more SIRS criteria (Vincent et al., 2013; Cohen et al.,
2015; Drewry and Hotchkiss, 2015; Kaukonen et al., 2015). In addition it has been
suggested that there is a need to target therapeutic interventions according to the
specific patient’s underlying pathophysiological processes, rather than looking for a
universal therapy that would be effective in the "typical” patient population with sepsis
(Boomer et al., 2014; Christaki and Giamarellos-Bourboulis, 2014).
The complex pathophysiology of sepsis and the ineffectiveness of current
targeted therapies suggest that treatments guided by biomarkers could provide a new
therapeutic strategy. A biomarker, as defined by an NIH working group, is “a
characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention” (Group, 2001). There are general and overlapping categories
of biomarkers, which have been reviewed and discussed in detail elsewhere (Marshall
et al., 2009; Kaplan and Wong, 2011; Dupuy et al., 2013; Sandquist and Wong, 2014).
Biomarker categories include 1) screening biomarkers to identify patients at increased
risk and inform on prophylactic interventions, 2) diagnostic biomarkers to establish the
presence or absence of disease and inform treatment decisions, 3) stratification
biomarkers to stage severity and outcome of disease and help identify subgroups of
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
8
patients who may benefit or be harmed by therapy, 4) monitoring biomarkers to inform
on the effectiveness of a therapy, and 5) surrogate biomarkers to inform on disease
progression and potential outcomes of therapy. A number of excellent recent reviews
have been published on the potential diagnostic and prognostic value of biomarkers in
sepsis (Pierrakos and Vincent, 2010; Sandquist and Wong, 2014; Biron et al., 2015;
Cohen et al., 2015). Therefore, this review will not focus on the current status of sepsis
biomarkers. Rather, the goal of this review is to support the concept that the appropriate
biomarkers could be used to direct targeted therapies (Fig. 1). For example, diagnostic
biomarkers could direct therapies such as those targeting immune status, endothelial
injury, coagulation, and microcirculatory failure; and stratification biomarkers could
inform the decision to rapidly employ renal replacement therapy or mechanical
ventilation.
Patient Heterogeneity
Both the incidence and the outcome of sepsis are greatly influenced by patient
heterogeneity including patient-specific factors such as age, comorbid medical
conditions, and genetic predispositions. The very young (<1 year) and the elderly (>65
years) account for 76% of all deaths due to sepsis in the U.S. (Heron, 2015). Premature
and very-low-birth-weight infants suffer the highest mortality (Heron, 2015), which may
be due to increased hemodynamic fragility, low cardiac output, and organ hypoperfusion,
as well as a decreased ability to mount an appropriate immune response (Adkins et al.,
2004; Aneja and Carcillo, 2011; Shah and Padbury, 2014). Likewise, in elderly patients,
debilitated physiological processes, reflected in higher incidences of congestive heart
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
9
failure, coronary artery disease, diabetes, hypertension, and chronic obstructive
pulmonary disease, underlie a 13-fold higher relative risk for the development of sepsis
(Martin et al., 2006) and an increased mortality from sepsis (Boss and Seegmiller, 1981).
These physiological differences in sepsis with respect to age and comorbid medical
conditions suggest that treatments will need to be based on the specific conditions of
the individual patient.
The presence of MODS is an important factor in the treatment of sepsis. While
there is substantial variation in the percentages of patients with any specific organ
involvement, pulmonary, renal, cardiovascular, hepatic, neurological, and hematological
dysfunction may result from primary and secondary causes (Gaieski et al., 2013;
Iskander et al., 2013; Stubbs et al., 2013; Ziaja, 2013; Fiusa et al., 2015). In all
populations, the mortality rate of sepsis greatly increases as multiple organ systems fail
(Gaieski et al., 2013; Iskander et al., 2013; Romanovsky et al., 2013).
Because of the inherent heterogeneity of patients enrolled in clinical trials, a level
of heterogeneity in the therapeutic response should be expected. Most important,
however, while some patients will benefit from the intervention, others could be harmed
(Marshall, 2014). To demonstrate overall efficacy of a treatment, studying larger
numbers of patients to increase statistical power is required in trial design, but this will
increase costs and may still not uncover efficacy in the general population for the
reasons just described. Early-phase sepsis trials should focus on identifying an
appropriate study population and use more specific inclusion criteria to limit trials to the
target populations suggested by preclinical studies. This approach could reduce
heterogeneity and increase the likelihood of demonstrating efficacy.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
10
Biomarkers
Validation of biomarkers requires an extensive amount of research and
resources. A limitation of biomarker research in human sepsis is that there are rarely
data on preillness levels of a biomarker. Because many septic patients have comorbid
chronic inflammatory conditions such as coronary artery disease and diabetes,
biomarkers alone are unlikely to accurately inform on the severity of sepsis (Ginde et al.,
2014) but may inform on possible outcomes (Kojic et al., 2015). For example, the ideal
biomarker could identify those patients at risk for specific organ dysfunction and thereby
help direct more targeted therapy. In addition, gene expression patterns could lead to
candidate serum protein markers to predict organ-specific injury (Basu et al., 2011).
Given the complex nature of sepsis, achieving this goal will likely require monitoring
multiple biomarkers through the course of the disease and the course of therapy (Wong
et al., 2015a). Biomarkers also depend on the specific pathogen, or often pathogens,
causing sepsis. Consequently, there is a need to accurately and quickly distinguish
sepsis from noninfectious SIRS. These are all areas where proteomics and genomics
(Cao and Robinson, 2014; Cao et al., 2014; Christaki and Giamarellos-Bourboulis,
2014; DeCoux et al., 2015) and rapid identification of positive blood cultures (Bhatti et
al., 2014b; Bhatti et al., 2014a) could become very helpful.
Inflammatory Biomarkers
Should the goal of therapy for septic patients be to decrease inflammation or
boost host immunity? This is an extremely important and difficult question with no
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
11
simple answer. Hotchkiss and Sherwood (Hotchkiss and Sherwood, 2015) have
published a recent commentary on this issue. However, biomarkers have the potential
to help critical care physicians make important clinical decisions regarding
immunotherapy (Hotchkiss et al., 2013b).
In general, blood levels of soluble adhesion molecules such as E-, L- and P-
selectin, ICAM-1, and VCAM-1 correlate with the presence of sepsis in neonates,
children, and adults; however, there are age-related differences in the absolute levels,
and it is still unclear whether changes in levels might correlate positively or negatively
with outcomes (Zonneveld et al., 2014). C-reactive protein (CRP) is an acute-phase
protein released by the liver. It is used as an inflammatory biomarker but cannot
distinguish between infection and noninfectious diseases (Kojic et al., 2015).
Procalcitonin (PCT) is a propeptide of calcitonin released in the blood in response
bacteria-associated proinflammatory mediators and inflammatory cytokines. Its use as a
specific biomarker for sepsis has come under question (Talan, 2015). CRP and PCT
may be more general biomarkers of moderate to severe inflammation but could be
useful for informing on the response to treatment (Wacker et al., 2013; Rule et al., 2015).
However, the levels of PCT and CRP in combination may be able discriminate bacterial
sepsis from other causes of SIRS (Han et al., 2015).
Cytokines including tumor necrosis factor α (TNF-α) and interleukin (IL)-1, IL-6,
IL-8, IL-27, and others have been evaluated individually and in combination as potential
biomarkers for screening and diagnosis (Xiao et al., 2015). Although cytokine levels are
relatively easily and rapidly measured with multiplex assays (Mera et al., 2011), the
cost–benefit of monitoring them has yet to be established. Serial cytokine
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
12
measurements would be required to inform on immune status; however, this would
require a thorough understanding of the complex kinetics of synthesis, release, and
clearance. Moreover, elderly septic patients present with generally higher levels of
inflammatory biomarkers due to comorbid conditions (Ginde et al., 2014), and because
pre-sepsis levels would be unknown, interpreting changes (or not) in cytokine levels
would be extremely difficulty. These issues may explain, at least in part, why clinical
trials targeting cytokines failed to demonstrate efficacy; use of some agents was even
harmful (Fink and Warren, 2014).
Septic patients in the immunosuppressive phase could potentially benefit from
immune-enhancing therapies, but these patients must first be identified. Potential
biomarkers, which have been suggested for this purpose, include decreased monocyte
human leukocyte antigen – antigen D related (HLA-DR) expression for monocyte
unresponsiveness, increased programmed cell death 1 (PD-1) expression for T cell
exhaustion, lymphopenia, and increased percentage of regulatory T cells, among others
(reviewed in (Hotchkiss et al., 2013b) and (Boomer et al., 2014)). The use of specific,
biomarker-directed immunotherapies such as granulocyte macrophage colony
stimulating factor (GM-CSF) to stimulate mature myeloid cell expansion in patients with
granulocytopenia (Mathias et al., 2015), and IL-7 to promote lymphocyte expansion in
patients with lymphopenia (Unsinger et al., 2010; Hutchins et al., 2014) are examples of
new therapeutic strategies with the potential to advance the treatment of the
immunosuppressed septic patient (Hotchkiss et al., 2013a; Boomer et al., 2014).
Endothelial Biomarkers
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
13
Sepsis is associated with severe injury to vascular endothelial cells. Injury to the
endothelium leads to dysregulation of vascular tone, hemostasis, and the permeability
barrier. Microvascular leakage is a hallmark of sepsis and results from damage to the
endothelial cell barrier lining the microvasculature. Identifying possible targeted therapy
to stabilize and even promote repair of the endothelial barrier is a very active area of
research (Darwish and Liles, 2013). Syndecan-1 and heparan sulfate are potential
biomarkers of damage to the endothelial glycocalyx, the antiadhesive and anticoagulant
surface of the endothelial cell (Schmidt et al., 2012) and, if confirmed as such, could be
used as diagnostic and monitoring biomarkers to direct and evaluate anticoagulant
therapy (Ostrowski et al., 2015; Yini et al., 2015).
A number of signaling pathways regulating vascular permeability appear to be
disrupted during sepsis. One such system is the endothelial-specific angiopoietin growth
factor (Ang) and its Tie-2 tyrosine kinase receptor (Maisonpierre et al., 1997; Ziegler et
al., 2013). Plasma levels of Ang-1, Ang-2, and Tie-2 have been show to predict the
onset of acute lung injury (Agrawal et al., 2013), 28-day mortality in septic adults (Fang
et al., 2015), and sepsis severity in children (Wang et al., 2014). If verified, levels of
Ang-1, Ang-2, and Tie-2 in septic patients may inform on the effectiveness and outcome
of therapy affecting the endothelium, such as the use of statins (Ghosh et al., 2015).
Another system is the sphingosine-1-phosphate (S1P) signaling pathway, a key
regulator of endothelial stability and vascular permeability (Lee et al., 1999; Wang and
Dudek, 2009). Serum levels of S1P in septic patients are decreased and inversely
associated with disease severity (Winkler et al., 2015). If S1P levels can be verified as a
biomarker of microvascular injury, S1P could be used to screen, diagnose, and/or
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
14
stratify patients and direct the use of S1P receptor 1 agonists, shown to protect the
endothelial glycocalyx in vitro (Zeng et al., 2014) and to heal the renal microcirculation
in a murine model of sepsis (Wang et al., 2015b).
During sepsis, injured endothelial cells release microparticles containing proteins
and lipids that can augment thrombosis, inflammation, and microvascular injury.
Understanding the role of microparticles in the progression of sepsis and organ injury is
also a very active area of research. Souza and colleagues (Souza et al., 2015) have
published an excellent recent review. As a potential biomarker, microparticles may help
stratify patients and inform on the potential outcomes of therapy targeting the
endothelium.
Coagulation Biomarkers
Sepsis with its associated inflammation induces a state of dysregulated
hemostasis. Up to 30–50% of septic patients have clinical overt disseminated
intravascular coagulation (DIC), which leads to dissemination of fibrin-rich microvascular
thromboses and contributes to MODS (Levi and van der Poll, 2013). Many specific
monotherapeutic agents that interfere with dysregulated hemostasis in septic patients
have been tried without success in large randomized, controlled trials. These agents
include heparin, antithrombin III, recombinant tissue pathway inhibitors, recombinant
activated protein C, and recombinant soluble thrombomodulin (Warren et al., 2001;
Abraham et al., 2003; Nadel et al., 2007; Saito et al., 2007; Jaimes et al., 2009; Ranieri
et al., 2012). These trials, however, enrolled heterogeneous septic patients and did not
use coagulation biomarkers as titratable therapeutic endpoints. On reflection, the failure
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
15
of these trials suggests that, as described earlier, study design and patient selection
rather than the specific agents may be at fault (Cohen et al., 2015). Currently, clinicians
rely on point-of-care global measurement of the hemostatic pathway including
prothrombin time, activated partial thromboplastin time, the fibrin degradation product D-
dimer, and platelet count to provide blood product support for hemostasis (Wada et al.,
2013). For future clinical trials, in addition to the point-of-care assays, measuring,
replacing, and normalizing the activities of heparin, antithrombin III, tissue factor,
activated protein C, and/or thrombomodulin in septic patients with a defined severe
coagulopathy perhaps might lead to better outcomes.
Sepsis-induced thrombotic microangiopathies driven by either von Willebrand
factor (VWF)/platelets and/or complement pathways will lead to dissemination of
VWF/platelet-rich microvascular thromboses and MODS (Nguyen et al., 2014;
Charchaflieh et al., 2015). Measuring VWF, the presence of ultralarge VWF multimers,
and ADAMTS-13 (VWF-cleaving protease) and directing therapies to normalize their
activities have been shown to improve outcome in children with sepsis-induced
thrombocytopenia-associated multiple organ failure (Nguyen et al., 2008; Fortenberry et
al., 2012). Low levels of ADAMTS-13, high VWF activity, and the presence of ultralarge
VWF multimers have been associated with worse outcomes in septic adults (Martin et
al., 2007; Bockmeyer et al., 2008). Sepsis-induced complement pathway dysregulation
leading to DIC and thrombotic microangiopathies has been demonstrated in human
clinical studies and animal models (Charchaflieh et al., 2015; Zhao et al., 2015).
Eculizumab, a monoclonal antibody against complement C5, has been shown to
improve outcome in severe Escherichia coli–induced hemolytic uremic syndrome, which
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
16
leads to thrombotic microangiopathy and MODS (Lapeyraque et al., 2011; Noris et al.,
2012). Research is needed to prove whether other types of infection-induced thrombotic
microangiopathy and MODS can be ameliorated by measuring and normalizing
complement activities.
Physiological Biomarkers
Biomarkers are generally assumed to mean small molecules. However,
physiological biomarkers are the most rapidly determined indices of organ dysfunction
and can often be measured at the bedside. The complex pathophysiology of sepsis can
have a major impact on the translation of experimental therapies to clinical practice.
This is one of the key reasons that animal models of sepsis have had, thus far, a limited
impact on therapy in humans (Dyson and Singer, 2009; Marshall, 2014; Efron et al.,
2015). Changes in cardiac output, organ perfusion, drug delivery to therapeutic target,
and clearance of the drug are dynamic and often unpredictable in septic patients.
Physiological biomarkers could be of great help in interpreting successes, failures, and
undesirable outcomes in sepsis clinical trials.
The application of transthoracic echocardiography with speckle-tracking
technology to detect subclinical myocardial dysfunction may have value in directing
cardioprotective strategies, even if the ejection fraction remains normal (Shahul et al.,
2015). This type of monitoring may also help in establishing prognosis in septic shock
patients because, despite a normal ejection fraction, severe right ventricular wall
longitudinal strain dysfunction is associated with a high rate of mortality in patients with
severe sepsis and septic shock (Orde et al., 2014). There is a pressing need for
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
17
biomarkers to screen for sepsis-induced cardiomyopathy. Extracellular histones may
emerge as such a biomarker (Alhamdi et al., 2015; Kalbitz et al., 2015).
There is also a need for minimally invasive techniques that permit direct
physiological measurements of microvascular flow and organ perfusion in critically ill
patients. One of the most routine measurements made in septic patients is blood lactate
concentration. Lactate production is a protective response to allow cellular energy
production to continue when tissue oxygen supply is inadequate for aerobic metabolism
(Suetrong and Walley, 2015). Serum lactate levels remain a strong, independent
predictor of lung injury (Mikkelsen et al., 2013). Elevated lactate levels are highly
associated with in-hospital mortality and can be used to stratify patient risk (Casserly et
al., 2015). Use of lactate as a biomarker to direct management of the microcirculation
during the later stages of sepsis can be complicated by changes in lactate clearance
(Chertoff et al., 2015). Better understanding of the relationships between lactate levels
and actual status of the microcirculation remains a critical need (De Backer et al., 2013).
Organ-specific microcirculation can be measured in animal models of
experimental sepsis and used to evaluate the therapeutic potential of new approaches
to improve organ perfusion (Dear et al., 2005; Wu et al., 2007; Holthoff et al., 2012; Fink
et al., 2013; Taccone et al., 2014). As therapeutic strategies emerge to target
microvascular dysfunction, physiological biomarkers measureable at the bedside could
assist in directing therapy and confirming efficacy (or revealing harmfulness) (Matejovic
et al., 2015). Cine phase-contrast MRI and contrast-enhanced ultrasound can be
performed on critically ill septic patients to monitor blood flow in the kidney (Schneider
et al., 2013). For example, cine phase-contrast MRI revealed that renal blood flow was
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
18
consistently reduced as a fraction of cardiac output in septic patients with established
acute kidney injury (Prowle et al., 2012). Although these minimally invasive techniques
for monitoring organ perfusion are still in the validation phase, their use could ultimately
guide the choice of therapy and evaluate effectiveness. For example, changes in renal
perfusion paired with renal injury biomarkers such as neutrophil gelatinase-associated
lipocalin (NGAL), kidney injury molecule 1 (KIM-1), N-acetyl-β-(D)-glucosaminidase
(NAG), and matrix metalloproteinase-8 (MMP-8) (Liangos et al., 2007; Basu et al., 2011;
Wang et al., 2015a) could direct the implementation of renal replacement therapies
(hemofiltration and/or dialysis) that could improve outcomes in some patients; however,
this approach is not without risk (Elseviers et al., 2010; Sun et al., 2014; Prowle and
Davenport, 2015; Wald et al., 2015).
Orthogonal polarization spectral imaging and side-stream dark-field imaging
techniques can be used at the bedside to obtain real-time measurements of the
sublingual microcirculation in humans with sepsis (De Backer et al., 2012). Even though
changes in the sublingual microcirculation cannot predict the status of other organ-
specific microvascular beds, there is an excellent correlation between decreases in the
proportion of perfused small sublingual vessels in early sepsis and decreased survival
rates (De Backer et al., 2013; De Backer et al., 2014). These techniques could be used
as diagnostic and monitoring physiological biomarkers to direct therapy targeting the
vasculature, as suggested in animal models of sepsis (Holthoff et al., 2013; Wang et al.,
2015b).
Sepsis-associated encephalopathy with cognitive impairment is a common
complication of sepsis that places a substantial burden on survivors of sepsis, their
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
19
families, and their caregivers (Iwashyna et al., 2010). While the pathophysiology is still
poorly understood, neuroinflammatory and ischemic process are likely contributors to
alterations in the blood–brain barrier, release of neurotoxic mediators, and microglial
activation (Adam et al., 2013). Changes in standard electroencephalogram (EEG) are
associated with increased mortality and delirium in septic ICU patients (Azabou et al.,
2015). Near-infrared spectroscopy (NIRS) is being evaluated in high-risk septic patients
as a method to monitor brain tissue oxygenation to predict the development of acute
neurological dysfunction (Wood et al., (in press)). Interest is growing in identifying
biomarkers for sepsis-induced neurological injury (Bersani et al., 2015), especially
because animal models are revealing long-term brain alterations that affect learning and
memory and persist into adulthood (Comim et al., 2015; Gao et al., 2015). Targeting
neurotoxic inflammatory pathways (Gao et al., 2015) may emerge as an approach that
could be guided by specific small-molecule and physiological biomarkers.
Accumulating data suggest that during sepsis intracellular redox processes result
in increased production of superoxide, hydrogen peroxide, and peroxynitrite, especially
in mitochondria (Mayeux and Macmillan-Crow, 2012; Duran-Bedolla et al., 2014). While
there are studies to suggest that mitochondrial injury occurs in septic patients (Jeger et
al., 2013), the notion that mitochondrial injury is a cause of organ dysfunction is
controversial (Fink, 2015). Nonetheless, if there were rapidly measurable mitochondrial
injury biomarkers, they could be used to direct mitochondria-targeted antioxidants, such
as ubiquinone (MitoQ), vitamin E (MitoVit E), and piperidine nitroxide (MitoTEMPO),
which have been shown in animal models to be protective against sepsis-induced
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
20
cardiomyopathy (Supavekin et al., 2003; Zang et al., 2012; Yao et al., 2015), renal injury
(Patil et al., 2014), and microcirculatory failure (Patil et al., 2014; Sims et al., 2014).
Combinations of Biomarkers
The heterogeneity of septic patients suggests that multiple biomarkers may be
required to effectively guide therapy (Gibot et al., 2012; Liu et al., 2014; Sandquist and
Wong, 2014). Wong and collaborators have begun to use panels of biomarkers to
stratify pediatric septic shock patients to predict risk (Wong et al., 2014) and possibly
inform on therapeutic decisions (Wong et al., 2015a; Wong et al., 2015b). For example,
the PERSEVERE study used a panel consisting of C-C chemokine ligand 3, IL-8, heat
shock protein 70 kDa 1B, granzyme B, and MMP-8 to stratify pediatric sepsis patients
based on mortality probability (Wong et al., 2014). A panel of candidate biomarker
genes has also been used to guide the use of adjuvant corticosteroids (Wong et al.,
2015b). Due to the complexity of sepsis and the diversity of patient populations, it
should expected that combinations of biomarkers (small molecule and physiological) will
be required to best inform on interventional therapies (Fig. 1).
Animal Models
Animal models of sepsis are the subject of a number of excellent reviews that
discuss advantages and disadvantages of the various species studied and the various
methods used to induce sepsis (Zanotti-Cavazzoni and Goldfarb, 2009; Ward, 2012;
Fink, 2013; Efron et al., 2015). It is clear that no animal model of sepsis can fully
replicate the complexities and range of sepsis in humans. However, animal models are
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
21
essential for preclinical testing of new therapies to help suggest dose, potential toxicities,
and efficacy. Animal models are also necessary to identify potential biomarkers and test
new monitoring modalities. From a basic science point of view, in vivo models of sepsis
provide a means to investigate underlying mechanisms of organ injury that are not
possible in very sick septic patients.
Murine and rat models of sepsis are the most frequently used because of their
relatively low cost and their public acceptance as laboratory subjects. However, just
how relevant murine models of inflammation are to inflammatory diseases is an area of
intense debate (Seok et al., 2013; Osuchowski et al., 2014; Efron et al., 2015). Larger
species, such as pigs, sheep, dogs, and subhuman primates, are also used in sepsis
research, and some of these species better replicate more of the “typical”
cardiovascular defects observed in humans with sepsis than do small animals (Zanotti-
Cavazzoni and Goldfarb, 2009; Taylor et al., 2012). Not surprisingly, however, large-
animal models are rarely used in survival studies. This is an important consideration
because increased mortality is a key measure of efficacy in sepsis clinical trials.
Because sepsis is defined as a systemic inflammatory response due to an
infection (Dellinger et al., 2013), the most clinically relevant models of sepsis should
incorporate both a systemic inflammatory response and an active infection. Models of
sepsis that utilize endotoxemia (lipopolysaccharide [LPS] from the outer membrane of
gram-negative bacteria) in rodents and larger species are less clinically relevant
because these models rely solely on rapid activation of the innate immune system and
do not replicate the consequences of active microbial defense and subsequent immune
suppression observed in humans with sepsis (Stearns-Kurosawa et al., 2011).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
22
In rodents, the cytokine profile and magnitude of cytokine release are very
different between endotoxemia models and active-infection models, such as
polymicrobial peritonitis induced by cecal ligation and puncture (CLP). LPS produces a
very rapid but transient increase in inflammatory cytokines to levels that can be orders
of magnitude higher than with CLP (Kawai et al., 1999; Remick et al., 2000; Miyaji et al.,
2003), where the magnitude and kinetics of cytokine release more closely mirror what
occurs in human sepsis (Rittirsch et al., 2007). Still, there are advantages to studying
endotoxemia. Endotoxemia models are attractive from an experimental point of view
because they are highly reproducible and do produce similar effects on the vasculature
(although perhaps through different mechanisms (Asano et al., 2015) and similar
mortality rates (Remick et al., 2000). A limitation of endotoxemia models is that the
systemic inflammatory effects are mediated through interactions with toll-like receptor-4
(TLR4) (Kawai et al., 1999; Palsson-McDermott and O'Neill, 2004), whereas this is not
the case in polymicrobial sepsis (Dear et al., 2006). These are mechanistically important
differences between endotoxin and polymicrobial models of sepsis that can impact the
translation of experimental therapies to clinical practice (Rittirsch et al., 2007).
Consequently, the CLP model and other models of active infection are generally
considered to be clinically relevant models of sepsis, especially when they incorporate
antibiotic and fluid therapy to more closely mimic the standard care of septic patients
(Miyaji et al., 2003; Rittirsch et al., 2007; Dyson and Singer, 2009; Rittirsch et al., 2009).
However, the CLP model exhibits high inherent variability because it depends on the
resident bacterial flora of the cecal contents, which can vary from animal to animal, and
on the consistency of a technician’s surgical skills.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
23
Depending on the dose, intravenous infusion of live E. coli in sheep can produce
mild hyperdynamic (increased cardiac output) sepsis or severe hypotensive sepsis
(Ramchandra et al., 2009; Ishikawa et al., 2011) to mimic the range of sepsis severity
and degree of cardiovascular dysfunction observed in humans. Similarly, in adult pigs,
intravenous administration of live bacteria can produce hypotensive sepsis associated
with pulmonary hypertension and a transient increase in systemic vascular resistance
(Garcia-Septien et al., 2010); in addition, when acute kidney injury develops, a
dissociation is produced between systemic hemodynamic changes and changes in the
renal circulation (Benes et al., 2011). In baboons, intravenous challenge with live E. coli
can be titrated to produce mild sepsis or severe sepsis with refractory hypotension and
coagulopathies (Taylor et al., 2012). An advantage of live-bacteria infusion models is
that gram-positive bacteria can also be studied (Soerensen et al., 2012), as well as
controlled combinations of bacteria. Another advantage of these intravenous live culture
models over the CLP model is that sepsis can be induced without subjecting the animal
to a surgical procedure or general anesthesia.
Autologous fecal peritonitis is a variation of the CLP model in which the cecal
contents are collected from an animal and administered at a later time. This model has
been used in sheep (He et al., 2012; Taccone et al., 2014) and pigs (Benes et al., 2011;
Correa et al., 2012; Wepler et al., 2013) to study sepsis-induced cardiovascular injury
and evaluate resuscitation protocols. A variation in which the fecal matter is derived
from multiple animals can also be used in mice too young or too small for the CLP
procedure (Wynn et al., 2007; Wynn et al., 2008). This model offers an additional
advantage in that cecal contents can be harvested from multiple animals, pooled,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
24
partially purified, stored at –80°C, and then administered to groups of animals (Starr et
al., 2014). The “dose” of fecal contents can be normalized to bacterial colony–forming
units (cfu)/body weight prior to administration, which should reduce interexperimental
variability.
As discussed earlier, sepsis is not identical in neonates, infants, and adults, and
it should not be assumed that results from adult animal models of sepsis are relevant for
translation to neonates or even infants with sepsis. Most preclinical studies are
performed in adult “middle-aged” animals, yet there are clear differences in the
immunological responses (Wynn et al., 2007; Wynn et al., 2008; Turnbull et al., 2009),
degree of organ injury (Miyaji et al., 2003; Starr et al., 2015), and mortality (Turnbull et
al., 2009; Starr et al., 2014) between very young, adult, and old mice made septic by
fecal peritonitis. CLP can be performed in young (weaning age) rat pups as a model of
infant sepsis. These animals develop rapid hemodynamic changes and microvascular
dysfunction that are not the same as in adult rats (Seely et al., 2011; Sims et al., 2014).
Neonatal, 3-day-old piglets subjected to CLP show deterioration of cardiac output,
pulmonary hypertension, and shock (Goto et al., 2010), consistent with cold shock (low
cardiac output with high systemic vascular resistance) frequently observed in newborns
and infants with severe sepsis (Wheeler et al., 2011).
Confounding comorbid or predisposing conditions of most septic patients limit the
translation of findings from most animal models. However, researchers are now
beginning to study the pathophysiology of sepsis in the presence of comorbid conditions,
such as chronic kidney disease (Doi et al., 2008; Leelahavanichkul et al., 2011), type 1
(Osuchowski et al., 2010; Filgueiras et al., 2012) and type 2 (Jacob et al., 2008)
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
25
diabetes, and atherosclerosis (Wepler et al., 2013). Such studies are especially
important because they could uncover more targeted therapy for comorbid conditions.
They could also help explain why a therapy fails in septic patients with preexisting
conditions (Doi et al., 2008; Leelahavanichkul et al., 2011; Filgueiras et al., 2012) or
why survivors of sepsis may have increased susceptibility to subsequent organ injury
(Portella et al., 2013).
Murine models of sepsis are also being used to investigate the development and
potential causes of cognitive impairments following sepsis like those observed in human
survivors of sepsis (Iwashyna et al., 2010). For example, mice surviving severe sepsis
induced by CLP show time-dependent learning and memory impairments (Chavan et al.,
2012; Ji et al., 2015) associated with dendritic degeneration (Chavan et al., 2012) and
oxidative stress in the prefrontal cortex and hippocampus (Ji et al., 2015).
Preclinical research has several important roles to play in the development of
novel therapeutics. However, animal models have limitations that weaken the prediction
of clinical efficacy. Still, animal models are necessary for the discovery of plausible
biological targets and the demonstration that these targets can be manipulated to
improve outcomes, at least in the experimental animal. Preclinical testing seeks to
identify targeted therapy that may be effective. Equally important, however, is the use of
preclinical testing to suggest ineffective or harmful therapies. For example,
administration of TNF-α-neutralizing antibody, while protective in most gram-negative
preclinical models, is actually detrimental in gram-positive bacteria models and some
other types of pathogens, perhaps due to inhibition of innate antimicrobial defenses
(Lorente and Marshall, 2005). Preclinical studies testing efficacy against sepsis-induced
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
26
multiorgan failure are more challenging (Andonegui et al., 2009; Kapoor et al., 2010;
Coldewey et al., 2013) but are necessary to support translational research and clinical
trials.
Personalized Medicine
Septic patients still experience unacceptably high morbidity and mortality, even
with optimal goal-directed supportive therapy that meets approved guidelines. It is
important to consider that the likelihood of survivors of severe sepsis to be readmitted to
an inpatient health care facility is higher than matched nonsepsis survivors (Prescott et
al., 2014). This is most likely related to the significant long-term physical and mental
disabilities that can affect survivors. For example, estimates are that sepsis-associated
alterations in mental status and cognitive deficits occur in up to 87% of septic patients
(Iwashyna et al., 2012). While decreasing mortality is and should be the goal of therapy,
it is becoming increasingly clear that patients who initially survive sepsis experience
functional deficits that can diminish quality of life and even increase long-term mortality.
Consequently, biomarkers that also direct therapies that decrease the morbidity of
survivors would have a major impact on the overall health care burden of sepsis (Fig. 2).
Biomarkers and rapid noninvasive monitoring could offer better and more rapid
stratification of patients to identify those who might benefit (or be harmed) by more
targeted therapies. The advent of high-throughput technologies and access to advanced
bioinformatics have made possible the concept of personalized medicine to direct
therapy in septic patients. A personalized medicine approach may have the best chance
of identifying specific strategies for such a diverse patient population. A systems biology
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
27
approach could complement the use of biomarkers to stratify patients, aid in prognosis,
and help identify subsets of patients who may benefit or be harmed by therapy (Tsalik et
al., 2015). However, the costs are high, and it is too early to know whether knowledge of
the blood metabolome, proteome, and transcriptome could really direct therapy.
Perspectives
In the near future, biomarkers could direct the therapy of septic patients in order
to achieve an optimal outcome. Cohen and colleagues (Cohen et al., 2015) suggested
that the ideal profile of a sepsis biomarker should have these characteristics: fast
kinetics, high sensitivity and specificity, fully automated technology, short turnaround
time, availability as point-of-care tests, and low cost. Many clinicians already use
biomarkers to suggest an active infection (CRP, PCT), estimate the severity of under-
resuscitated septic shock (mixed venous blood oxygen saturation, lactate), and estimate
the severity of organ injury due to sepsis (liver enzymes, troponin, creatinine, ratio of
partial pressure of oxygen to fractional inspired oxygen, platelet count, activated partial
thromboplastin time, fibrinogen and D-dimer). Physiological biomarker monitoring
including echocardiography, pulmonary artery catheter, Doppler ultrasound, and/or
continuous pulse-contour cardiac analysis is already being used to direct sepsis
resuscitation and is recommended in the “Surviving Sepsis Campaign” document
(Dellinger et al., 2013).
After more than three decades of numerous failed large sepsis clinical trials,
sepsis is currently being redefined, which will most likely include “MODS due to non-
resolving inflammatory response to infection.” Future clinical trials of sepsis therapies
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
28
will most likely target an individual patient’s underlying pathophysiological mechanism
rather than a general patient population with sepsis. Some of the current proposed
mechanisms for sepsis-induced MODS include pathological immune activation,
immunoparalysis, mitochondrial dysfunction, disseminated microvascular thromboses,
and others (Carcillo et al., 2011). The genetic makeup of the host and pathological
organism, sex and age of the host, environmental factors, and specific interventions
from different hospitals will all influence the underlying pathophysiological mechanism of
the individual septic patient (Rautanen et al., 2015; Srinivasan et al., 2015). In this
context, future real-time measurements of biomarkers could identify the pathological
mechanism and direct therapeutic strategies in septic patients, including immune
modulation for pathological immune activation, boosting the immune response for
immunoparalysis, optimizing/rescuing mitochondrial function, reducing oxidative stress,
and/or normalizing dysregulated hemostasis. Eventually, more advanced physiological
monitoring, such as assessment of the microcirculation of specific organs, will give
instantaneous feedback of intervention where titration of therapeutic agents could be
optimized.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
29
Authorship Contributions
Participated in research design: NA.
Conducted experiments: NA.
Contributed new reagents or analytic tools: NA.
Performed data analysis: NA.
Wrote or contributed to the writing of the manuscript: Sims, Nguyen, Mayeux.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
30
References
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P,
Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De
Deyne C, Postier R, Pettila V, Sprung CL, Artigas A, Percell SR, Shu V,
Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA and Group OTS
(2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway
inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc
290:238-247.
Adam N, Kandelman S, Mantz J, Chretien F and Sharshar T (2013) Sepsis-induced
brain dysfunction. Expert Rev Anti Infect Ther 11:211-221.
Adkins B, Leclerc C and Marshall-Clarke S (2004) Neonatal adaptive immunity comes
of age. Nat Rev Immunol 4:553-564.
Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, Cortez A, Abbott J,
Liu KD and Calfee CS (2013) Plasma angiopoietin-2 predicts the onset of acute
lung injury in critically ill patients. Am J Respir Crit Care Med 187:736-742.
Alhamdi Y, Abrams ST, Cheng Z, Jing S, Su D, Liu Z, Lane S, Welters I, Wang G and
Toh CH (2015) Circulating Histones Are Major Mediators of Cardiac Injury in
Patients With Sepsis. Crit Care Med 43:2094-2103.
Andonegui G, Goring K, Liu D, McCafferty DM and Winston BW (2009) Characterization
of S. pneumoniae pneumonia-induced multiple organ dysfunction syndrome: an
experimental mouse model of gram-positive sepsis. Shock 31:423-428.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
31
Aneja RK and Carcillo JA (2011) Differences between adult and pediatric septic shock.
Minerva Anestesiol 77:986-992.
Asano S, Manne ND, Nandyala G, Ma B, Selvaraj V, Ravikumar A, Rice KM and Blough
E (2015) Cecal inoculum peritonitis: An alternative model for sepsis vascular
dysfunction study. Life Sci 141:108-118.
Azabou E, Magalhaes E, Braconnier A, Yahiaoui L, Moneger G, Heming N, Annane D,
Mantz J, Chretien F, Durand MC, Lofaso F, Porcher R, Sharshar T and Groupe
d'Explorations Neurologiques en R (2015) Early Standard Electroencephalogram
Abnormalities Predict Mortality in Septic Intensive Care Unit Patients. PLoS One
10:e0139969.
Basu RK, Standage SW, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N,
Meyer K, Checchia PA, Lin R, Shanley TP, Bigham MT, Wheeler DS, Devarajan
P, Goldstein SL and Wong HR (2011) Identification of candidate serum
biomarkers for severe septic shock-associated kidney injury via microarray. Crit
Care 15:R273.
Benes J, Chvojka J, Sykora R, Radej J, Krouzecky A, Novak I and Matejovic M (2011)
Searching for mechanisms that matter in early septic acute kidney injury: an
experimental study. Crit Care 15:R256.
Bersani I, Auriti C, Ronchetti MP, Prencipe G, Gazzolo D and Dotta A (2015) Use of
early biomarkers in neonatal brain damage and sepsis: state of the art and future
perspectives. Biomed Res Int 2015:253520.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
32
Bhatti MM, Boonlayangoor S, Beavis KG and Tesic V (2014a) Evaluation of FilmArray
and Verigene systems for rapid identification of positive blood cultures. J Clin
Microbiol 52:3433-3436.
Bhatti MM, Boonlayangoor S, Beavis KG and Tesic V (2014b) Rapid identification of
positive blood cultures by matrix-assisted laser desorption ionization-time of flight
mass spectrometry using prewarmed agar plates. J Clin Microbiol 52:4334-4338.
Biron BM, Ayala A and Lomas-Neira JL (2015) Biomarkers for Sepsis: What Is and
What Might Be? Biomark Insights 10:7-17.
Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Losche W,
Reinhart K and Brunkhorst FM (2008) Inflammation-associated ADAMTS13
deficiency promotes formation of ultra-large von Willebrand factor.
Haematologica 93:137-140.
Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125-
1128.
Boomer JS, Green JM and Hotchkiss RS (2014) The changing immune system in
sepsis: is individualized immuno-modulatory therapy the answer? Virulence 5:45-
56.
Boss GR and Seegmiller JE (1981) Age-related physiological changes and their clinical
significance. West J Med 135:434-440.
Cao Z and Robinson RA (2014) The role of proteomics in understanding biological
mechanisms of sepsis. Proteomics Clin Appl 8:35-52.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
33
Cao Z, Yende S, Kellum JA, Angus DC and Robinson RA (2014) Proteomics reveals
age-related differences in the host immune response to sepsis. J Proteome Res
13:422-432.
Carcillo JA, Han YY, Doughty L, Hall M, Nguyen TC and Aneja R (2011) Inflammation
and Immunity: Systemic Inflammatory Response Syndrome, Sepsis, Acute Lung
Injury, and Multiple Organ Failure, in Fuhrman & Zimmerman’s Pediatric Critical
Care 4th edition (Fuhrman B ZJ, Carcillo J, Clark R, Rotta A, Tobias J, Relvas M,
Thompson A ed), Elsevier.
Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, Reinhart K,
Selvakumar N and Levy MM (2015) Lactate measurements in sepsis-induced
tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit
Care Med 43:567-573.
Chang DW, Tseng CH and Shapiro MF (2015) Rehospitalizations Following Sepsis:
Common and Costly. Crit Care Med 43:2085-2093.
Charchaflieh J, Rushbrook J, Worah S and Zhang M (2015) Activated Complement
Factors as Disease Markers for Sepsis. Dis Markers 2015:382463.
Chavan SS, Huerta PT, Robbiati S, Valdes-Ferrer SI, Ochani M, Dancho M, Frankfurt M,
Volpe BT, Tracey KJ and Diamond B (2012) HMGB1 mediates cognitive
impairment in sepsis survivors. Mol Med 18:930-937.
Chertoff J, Chisum M, Garcia B and Lascano J (2015) Lactate kinetics in sepsis and
septic shock: a review of the literature and rationale for further research. J
Intensive Care 3:39.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
34
Christaki E and Giamarellos-Bourboulis EJ (2014) The beginning of personalized
medicine in sepsis: small steps to a bright future. Clin Genet 86:56-61.
Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, Jaton K,
Giulieri S, Delaloye J, Opal S, Tracey K, van der Poll T and Pelfrene E (2015)
Sepsis: a roadmap for future research. Lancet Infect Dis 15:581-614.
Coldewey SM, Rogazzo M, Collino M, Patel NS and Thiemermann C (2013) Inhibition of
IkappaB kinase reduces the multiple organ dysfunction caused by sepsis in the
mouse. Dis Model Mech 6:1031-1042.
Comim CM, Bussmann RM, Simao SR, Ventura L, Freiberger V, Patricio JJ, Palmas D,
Mendonca BP, Cassol-Jr OJ and Quevedo J (2015) Experimental Neonatal
Sepsis Causes Long-Term Cognitive Impairment. Mol Neurobiol:in press.
Conference NAC (1992) American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference: definitions for sepsis and organ failure and
guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-
874.
Correa TD, Vuda M, Blaser AR, Takala J, Djafarzadeh S, Dunser MW, Silva E, Lensch
M, Wilkens L and Jakob SM (2012) Effect of treatment delay on disease severity
and need for resuscitation in porcine fecal peritonitis. Crit Care Med 40:2841-
2849.
Darwish I and Liles WC (2013) Emerging therapeutic strategies to prevent infection-
related microvascular endothelial activation and dysfunction. Virulence 4:572-582.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
35
Daviaud F, Grimaldi D, Dechartres A, Charpentier J, Geri G, Marin N, Chiche JD,
Cariou A, Mira JP and Pene F (2015) Timing and causes of death in septic shock.
Ann Intensive Care 5:58.
De Backer D, Donadello K and Cortes DO (2012) Monitoring the microcirculation. J Clin
Monit Comput 26:361-366.
De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S and
Vincent JL (2013) Microcirculatory alterations in patients with severe sepsis:
impact of time of assessment and relationship with outcome. Crit Care Med
41:791-799.
De Backer D, Orbegozo Cortes D, Donadello K and Vincent JL (2014) Pathophysiology
of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence
5:73-79.
Dear JW, Kobayashi H, Jo SK, Holly MK, Hu X, Yuen PS, Brechbiel MW and Star RA
(2005) Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of
sepsis-induced acute renal failure in aged mice. Kidney Int 67:2159-2167.
Dear JW, Yasuda H, Hu X, Hieny S, Yuen PS, Hewitt SM, Sher A and Star RA (2006)
Sepsis-induced organ failure is mediated by different pathways in the kidney and
liver: Acute renal failure is dependent on MyD88 but not renal cell apoptosis.
Kidney Int 69:832-836.
DeCoux A, Tian Y, DeLeon-Pennell KY, Nguyen NT, de Castro Bras LE, Flynn ER,
Cannon PL, Griswold ME, Jin YF, Puskarich MA, Jones AE and Lindsey ML
(2015) Plasma Glycoproteomics Reveals Sepsis Outcomes Linked to Distinct
Proteins in Common Pathways. Crit Care Med 43:2049-2058.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
36
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE,
Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR,
Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld
GD, Webb SA, Beale RJ, Vincent JL, Moreno R and Surviving Sepsis Campaign
Guidelines Committee including the Pediatric S (2013) Surviving sepsis
campaign: international guidelines for management of severe sepsis and septic
shock: 2012. Crit Care Med 41:580-637.
Doi K, Leelahavanichkul A, Hu X, Sidransky KL, Zhou H, Qin Y, Eisner C, Schnermann
J, Yuen PS and Star RA (2008) Pre-existing renal disease promotes sepsis-
induced acute kidney injury and worsens outcome. Kidney Int 74:1017-1025.
Drewry AM and Hotchkiss RS (2015) Sepsis: Revising definitions of sepsis. Nat Rev
Nephrol 11:326-328.
Dupuy AM, Philippart F, Pean Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE,
Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J,
Gauzit R, Misset B, Brun-Buisson C and Maurice Rapin Institute Biomarkers G
(2013) Role of biomarkers in the management of antibiotic therapy: an expert
panel review: I - currently available biomarkers for clinical use in acute infections.
Ann Intensive Care 3:22.
Duran-Bedolla J, Montes de Oca-Sandoval MA, Saldana-Navor V, Villalobos-Silva JA,
Rodriguez MC and Rivas-Arancibia S (2014) Sepsis, mitochondrial failure and
multiple organ dysfunction. Clin Invest Med 37:E58-E69.
Dyson A and Singer M (2009) Animal models of sepsis: why does preclinical efficacy fail
to translate to the clinical setting? Crit Care Med 37:S30-S37.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
37
Efron PA, Mohr AM, Moore FA and Moldawer LL (2015) The future of murine sepsis
and trauma research models. J Leukoc Biol 98:945-952.
Elseviers MM, Lins RL, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J
and investigators S (2010) Renal replacement therapy is an independent risk
factor for mortality in critically ill patients with acute kidney injury. Crit Care
14:R221.
Fang Y, Li C, Shao R, Yu H, Zhang Q and Zhao L (2015) Prognostic significance of the
angiopoietin-2/angiopoietin-1 and angiopoietin-1/Tie-2 ratios for early sepsis in
an emergency department. Crit Care 19:367.
Filgueiras LR, Jr., Martins JO, Serezani CH, Capelozzi VL, Montes MB and Jancar S
(2012) Sepsis-induced acute lung injury (ALI) is milder in diabetic rats and
correlates with impaired NFkB activation. PLoS One 7:e44987.
Fink MP (2013) Animal models of sepsis. Virulence 5:143-153.
Fink MP (2015) Cytopathic hypoxia and sepsis: is mitochondrial dysfunction
pathophysiologically important or just an epiphenomenon. Pediatr Crit Care Med
16:89-91.
Fink MP and Warren HS (2014) Strategies to improve drug development for sepsis. Nat
Rev Drug Discov 13:741-758.
Fink T, Heymann P, Taha-Melitz S, Taha A, Wolf B, Rensing H, Volk T and Mathes AM
(2013) Dobutamine pretreatment improves survival, liver function, and hepatic
microcirculation after polymicrobial sepsis in rat. Shock 40:129-135.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
38
Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM and De Paula EV (2015)
Causes and consequences of coagulation activation in sepsis: an evolutionary
medicine perspective. BMC Med 13:105.
Fortenberry JD, Knezevic A, Nguyen TC and Group TNS (2012) Outcome in Childrens
on ECMO with TAMOF Receiving Plasma Exchange: Results from the
Prospective Pediatric TAMOF Network Study Crit Care Med 40:A520.
Gaieski DF, Edwards JM, Kallan MJ and Carr BG (2013) Benchmarking the incidence
and mortality of severe sepsis in the United States. Crit Care Med 41:1167-1174.
Gao R, Kan MQ, Wang SG, Yang RH and Zhang SG (2015) Disrupted Tryptophan
Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-
associated Encephalopathy. Inflammation:in press.
Garcia-Septien J, Lorente JA, Delgado MA, de Paula M, Nin N, Moscoso A, Sanchez-
Ferrer A, Perez-Vizcaino F and Esteban A (2010) Levosimendan increases portal
blood flow and attenuates intestinal intramucosal acidosis in experimental septic
shock. Shock 34:275-280.
Ghosh CC, Thamm K, Berghelli AV, Schrimpf C, Maski MR, Abid T, Milam KE,
Rajakumar A, Santel A, Kielstein JT, Ahmed A, Thickett D, Wang K, Chase M,
Donnino MW, Aird WC, Haller H, David S and Parikh SM (2015) Drug
Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in
Sepsis. Crit Care Med 43:e230-240.
Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, De Carvalho
Bittencourt M, Quenot JP, Bollaert PE, Faure G and Charles PE (2012)
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
39
Combination biomarkers to diagnose sepsis in the critically ill patient. Am J
Respir Crit Care Med 186:65-71.
Ginde AA, Blatchford PJ, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM,
Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, Gaieski DF, Goyal M, Cairns
CB, Rivers EP and Shapiro NI (2014) Age-related differences in biomarkers of
acute inflammation during hospitalization for sepsis. Shock 42:99-107.
Goto T, Hussein MH, Kato S, Daoud GA, Kato T, Kakita H, Mizuno H, Imai M, Ito T,
Kato I, Suzuki S, Okada N, Togari H and Okada H (2010) Endothelin receptor
antagonist attenuates inflammatory response and prolongs the survival time in a
neonatal sepsis model. Intensive Care Med 36:2123-2139.
Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and
conceptual framework. Clin Pharmacol Ther 69:89-95.
Gustot T (2011) Multiple organ failure in sepsis: prognosis and role of systemic
inflammatory response. Curr Opin Crit Care 17:153-159.
Han JH, Nachamkin I, Coffin SE, Gerber JS, Fuchs B, Garrigan C, Han X, Bilker WB,
Wise J, Tolomeo P, Lautenbach E, Prevention Epicenters Program of the
Centers for Disease C and Prevention (2015) Use of a Combination Biomarker
Algorithm To Identify Medical Intensive Care Unit Patients with Suspected Sepsis
at Very Low Likelihood of Bacterial Infection. Antibicrob Agents Chemother
59:6494-6500.
Hartman ME, Linde-Zwirble WT, Angus DC and Watson RS (2013) Trends in the
epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 14:686-693.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
40
He X, Su F, Velissaris D, Salgado DR, de Souza Barros D, Lorent S, Taccone FS,
Vincent JL and De Backer D (2012) Administration of tetrahydrobiopterin
improves the microcirculation and outcome in an ovine model of septic shock.
Crit Care Med 40:2833-2840.
Heron M (2015) Deaths: Leading Causes for 2011. National Vital Statistics Reports
64:1-96.
Holthoff JH, Wang Z, Patil NK, Gokden N and Mayeux PR (2013) Rolipram improves
renal perfusion and function during sepsis in the mouse. J Pharmacol Exp Ther
347:357-364.
Holthoff JH, Wang Z, Seely KA, Gokden N and Mayeux PR (2012) Resveratrol
improves renal microcirculation, protects the tubular epithelium, and prolongs
survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int
81:370-378.
Hotchkiss RS, Monneret G and Payen D (2013a) Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. Lancet Infect Dis
13:260-268.
Hotchkiss RS, Monneret G and Payen D (2013b) Sepsis-induced immunosuppression:
from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862-874.
Hotchkiss RS and Sherwood ER (2015) Getting sepsis therapy right. Science 347:1201-
1202.
Hutchins NA, Unsinger J, Hotchkiss RS and Ayala A (2014) The new normal:
immunomodulatory agents against sepsis immune suppression. Trends Mol Med
20:224-233.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
41
Ishikawa K, Bellomo R and May CN (2011) The impact of intrarenal nitric oxide
synthase inhibition on renal blood flow and function in mild and severe
hyperdynamic sepsis. Crit Care Med 39:770-776.
Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D,
Valentine C and Remick DG (2013) Sepsis: multiple abnormalities,
heterogeneous responses, and evolving understanding. Physiol Rev 93:1247-
1288.
Iwashyna TJ, Cooke CR, Wunsch H and Kahn JM (2012) Population burden of long-
term survivorship after severe sepsis in older Americans. J Am Geriatr Soc
60:1070-1077.
Iwashyna TJ, Ely EW, Smith DM and Langa KM (2010) Long-term cognitive impairment
and functional disability among survivors of severe sepsis. J Am Med Assoc
304:1787-1794.
Jacob A, Steinberg ML, Yang J, Dong W, Ji Y and Wang P (2008) Sepsis-induced
inflammation is exacerbated in an animal model of type 2 diabetes. Int J Clin Exp
Med 1:22-31.
Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D and Munoz A
(2009) Unfractioned heparin for treatment of sepsis: A randomized clinical trial
(The HETRASE Study). Crit Care Med 37:1185-1196.
Jeger V, Djafarzadeh S, Jakob SM and Takala J (2013) Mitochondrial function in sepsis.
Eur J Clin Invest 43:532-542.
Ji MH, Qiu LL, Tang H, Ju LS, Sun XR, Zhang H, Jia M, Zuo ZY, Shen JC and Yang JJ
(2015) Sepsis-induced selective parvalbumin interneuron phenotype loss and
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
42
cognitive impairments may be mediated by NADPH oxidase 2 activation in mice.
J Neuroinflammation 12:182.
Kalbitz M, Grailer JJ, Fattahi F, Jajou L, Herron TJ, Campbell KF, Zetoune FS,
Bosmann M, Sarma JV, Huber-Lang M, Gebhard F, Loaiza R, Valdivia HH, Jalife
J, Russell MW and Ward PA (2015) Role of extracellular histones in the
cardiomyopathy of sepsis. FASEB J.
Kaplan JM and Wong HR (2011) Biomarker discovery and development in pediatric
critical care medicine. Pediatr Crit Care Med 12:165-173.
Kapoor A, Shintani Y, Collino M, Osuchowski MF, Busch D, Patel NS, Sepodes B,
Castiglia S, Fantozzi R, Bishop-Bailey D, Mota-Filipe H, Yaqoob MM, Suzuki K,
Bahrami S, Desvergne B, Mitchell JA and Thiemermann C (2010) Protective role
of peroxisome proliferator-activated receptor-beta/delta in septic shock. Am J
Respir Crit Care Med 182:1506-1515.
Kaukonen KM, Bailey M, Pilcher D, Cooper DJ and Bellomo R (2015) Systemic
inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med
372:1629-1638.
Kawai T, Adachi O, Ogawa T, Takeda K and Akira S (1999) Unresponsiveness of
MyD88-deficient mice to endotoxin. Immunity 11:115-122.
Kissoon N, Carcillo JA, Espinosa V, Argent A, Devictor D, Madden M, Singhi S, van der
Voort E, Latour J and Global Sepsis Initiative Vanguard Center C (2011) World
Federation of Pediatric Intensive Care and Critical Care Societies: Global Sepsis
Initiative. Pediatr Crit Care Med 12:494-503.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
43
Kojic D, Siegler BH, Uhle F, Lichtenstern C, Nawroth PP, Weigand MA, Hofer S and
Brenner T (2015) Are there new approaches for diagnosis, therapy guidance and
outcome prediction of sepsis? World J Exp Med 5:50-63.
Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M,
Proulx F, Clermont MJ, Le Deist F, Niaudet P and Schaefer F (2011) Eculizumab
in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561-2563.
Laszlo I, Trasy D, Molnar Z and Fazakas J (2015) Sepsis: From Pathophysiology to
Individualized Patient Care. J Immunol Res 2015:510436.
Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI and
Hla T (1999) Vascular endothelial cell adherens junction assembly and
morphogenesis induced by sphingosine-1-phosphate. Cell 99:301-312.
Leelahavanichkul A, Huang Y, Hu X, Zhou H, Tsuji T, Chen R, Kopp JB, Schnermann J,
Yuen PS and Star RA (2011) Chronic kidney disease worsens sepsis and sepsis-
induced acute kidney injury by releasing High Mobility Group Box Protein-1.
Kidney Int 80:1198-1211.
Levi M and van der Poll T (2013) Disseminated intravascular coagulation: a review for
the internist. Intern Emerg Med 8:23-32.
Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon
RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV and Jaber BL (2007)
Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1
level are associated with adverse outcomes in acute renal failure. J Am Soc
Nephrol 18:904-912.
Liu X, Ren H and Peng D (2014) Sepsis biomarkers: an omics perspective. Front Med.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
44
Lorente JA and Marshall JC (2005) Neutralization of tumor necrosis factor in preclinical
models of sepsis. Shock 24 Suppl 1:107-119.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C,
Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN
and Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that
disrupts in vivo angiogenesis. Science 277:55-60.
Marshall JC (2014) Why have clinical trials in sepsis failed? Trends Mol Med 20:195-
203.
Marshall JC, Reinhart K and International Sepsis F (2009) Biomarkers of sepsis. Crit
Care Med 37:2290-2298.
Martin GS (2012) Sepsis, severe sepsis and septic shock: changes in incidence,
pathogens and outcomes. Expert Rev Mol Med 10:701-706.
Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H,
Legendre P, Diehl JL and Baruch D (2007) Decreased ADAMTS-13 (A
disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is
associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med
35:2375-2382.
Matejovic M, Ince C, Chawla LS, Blantz R, Molitoris BA, Rosner MH, Okusa MD, Kellum
JA, Ronco C and Group AXW (2015) Renal Hemodynamics in AKI: In Search of
New Treatment Targets. J Am Soc Nephrol 27:49-58.
Mathias B, Szpila BE, Moore FA, Efron PA and Moldawer LL (2015) A Review of GM-
CSF Therapy in Sepsis. Medicine (Baltimore) 94:e2044.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
45
Mayeux PR and Macmillan-Crow LA (2012) Pharmacological targets in the renal
peritubular microenvironment: Implications for therapy for sepsis-induced acute
kidney injury. Pharmacol Ther 134:139-155.
Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, Carstina D and
Oltean M (2011) Multiplex cytokine profiling in patients with sepsis. APMIS
119:155-163.
Mikkelsen ME, Shah CV, Meyer NJ, Gaieski DF, Lyon S, Miltiades AN, Goyal M, Fuchs
BD, Bellamy SL and Christie JD (2013) The epidemiology of acute respiratory
distress syndrome in patients presenting to the emergency department with
severe sepsis. Shock 40:375-381.
Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM and Star RA (2003) Ethyl
pyruvate decreases sepsis-induced acute renal failure and multiple organ
damage in aged mice. Kidney Int 64:1620-1631.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA,
Levy H, Angle R, Wang D, Sundin DP, Giroir B, Sepsis REs and Organ
dysfunction in children: a gLobal perspective study g (2007) Drotrecogin alfa
(activated) in children with severe sepsis: a multicentre phase III randomised
controlled trial. Lancet 369:836-843.
Nguyen TC, Han Y, Zhou Z, Fortenberry J, Cruz MA and Carcillo JA (2014)
Thrombocytopenia-Associated Multiple Organ Failure, in Pediatric Critical Care
Medicine: Basic Science and Clinical Evidence (Wheeler W, Shanley ed).
Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J and
Carcillo JA (2008) Intensive plasma exchange increases a disintegrin and
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
46
metalloprotease with thrombospondin motifs-13 activity and reverses organ
dysfunction in children with thrombocytopenia-associated multiple organ failure.
Crit Care Med 36:2878-2887.
Noris M, Mescia F and Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all
diseases of complement activation. Nat Rev Nephrol 8:622-633.
Orde SR, Pulido JN, Masaki M, Gillespie S, Spoon JN, Kane GC and Oh JK (2014)
Outcome prediction in sepsis: speckle tracking echocardiography based
assessment of myocardial function. Crit Care 18:R149.
Ostrowski SR, Haase N, Muller RB, Moller MH, Pott FC, Perner A and Johansson PI
(2015) Association between biomarkers of endothelial injury and
hypocoagulability in patients with severe sepsis: a prospective study. Crit Care
19:191.
Osuchowski MF, Craciun FL, Schuller E, Sima C, Gyurko R and Remick DG (2010)
Untreated type 1 diabetes increases sepsis-induced mortality without inducing a
prelethal cytokine response. Shock 34:369-376.
Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, Azevedo LC,
Bahrami S, Boros M, Cooney R, Cuzzocrea S, Jiang Y, Junger WG, Hirasawa H,
Hotchkiss RS, Li XA, Radermacher P, Redl H, Salomao R, Soebandrio A,
Thiemermann C, Vincent JL, Ward P, Yao YM, Yu HP, Zingarelli B and Chaudry
IH (2014) Abandon the mouse research ship? Not just yet! Shock 41:463-475.
Palsson-McDermott EM and O'Neill LA (2004) Signal transduction by the
lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113:153-162.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
47
Patil NK, Parajuli N, Macmillan-Crow LA and Mayeux PR (2014) Inactivation of renal
mitochondrial respiratory complexes and manganese superoxide dismutase
during sepsis: mitochondria targeted antioxidant mitigates injury. Am J Physiol
Renal Physiol 306:F734-F743.
Pierrakos C and Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15.
Portella VG, Silva-Filho JL, Landgraf SS, de Rico TB, Vieira MA, Takiya CM, Souza MC,
Henriques MG, Canetti C, Pinheiro AA, Benjamim CF and Caruso-Neves C
(2013) Sepsis-Surviving Mice Are More Susceptible to a Secondary Kidney Insult.
Crit Care Med 41:1056-1068.
Prescott HC, Langa KM, Liu V, Escobar GJ and Iwashyna TJ (2014) Increased 1-year
healthcare use in survivors of severe sepsis. Am J Respir Crit Care Med 190:62-
69.
Prowle JR and Davenport A (2015) Does early-start renal replacement therapy improve
outcomes for patients with acute kidney injury? Kidney Int 88:670-673.
Prowle JR, Molan MP, Hornsey E and Bellomo R (2012) Measurement of renal blood
flow by phase-contrast magnetic resonance imaging during septic acute kidney
injury: a pilot investigation. Crit Care Med 40:1768-1776.
Ramchandra R, Wan L, Hood SG, Frithiof R, Bellomo R and May CN (2009) Septic
shock induces distinct changes in sympathetic nerve activity to the heart and
kidney in conscious sheep. Am J Physiol Regul Integr Comp Physiol 297:R1247-
R1253.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B,
Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
48
Thompson V, Janes J, Macias WL, Vangerow B, Williams MD and Group P-SS
(2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med
366:2055-2064.
Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks
T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T,
Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V,
Sarapuu S, Kobilay M, Ranieri VM, Rello J, Sirgo G, Weiss YG, Russwurm S,
Schneider EM, Reinhart K, Holloway PA, Knight JC, Garrard CS, Russell JA,
Walley KR, Stuber F, Hill AV, Hinds CJ and Investigators EEG (2015) Genome-
wide association study of survival from sepsis due to pneumonia: an
observational cohort study. Lancet Respiratory Medicine 3:53-60.
Remick DG, Newcomb DE, Bolgos GL and Call DR (2000) Comparison of the mortality
and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal
ligation and puncture. Shock 13:110-116.
Rittirsch D, Hoesel LM and Ward PA (2007) The disconnect between animal models of
sepsis and human sepsis. J Leukoc Biol 81:137-143.
Rittirsch D, Huber-Lang MS, Flierl MA and Ward PA (2009) Immunodesign of
experimental sepsis by cecal ligation and puncture. Nat Protoc 4:31-36.
Romanovsky A, Morgan C and Bagshaw SM (2013) Pathophysiology and management
of septic acute kidney injury. Pediatr Nephrol 29:1-12.
Rule JA, Hynan LS, Attar N, Sanders C, Korzun WJ, Lee WM and Acute Liver Failure
Study G (2015) Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in
Acute Liver Failure. PLoS One 10:e0138566.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
49
Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK and Hebbar KB (2014)
Pediatric severe sepsis: current trends and outcomes from the Pediatric Health
Information Systems database. Pediatr Crit Care Med 15:828-838.
Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A,
Matsuda T, Asakura H, Nakashima M and Aoki N (2007) Efficacy and safety of
recombinant human soluble thrombomodulin (ART-123) in disseminated
intravascular coagulation: results of a phase III, randomized, double-blind clinical
trial. J Thromb Haemost 5:31-41.
Sandquist M and Wong HR (2014) Biomarkers of sepsis and their potential value in
diagnosis, prognosis and treatment. Expert Rev Clin Immunol 10:1349-1356.
Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL,
Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH,
Thompson KR, Geraci MW, Douglas IS, Pearse DB and Tuder RM (2012) The
pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury
during experimental sepsis. Nat Med 18:1217-1223.
Schneider AG, Goodwin MD and Bellomo R (2013) Measurement of kidney perfusion in
critically ill patients. Crit Care 17:220.
Seely KA, Holthoff JH, Burns ST, Wang Z, Thakali KM, Gokden N, Rhee SW and
Mayeux PR (2011) Hemodynamic changes in the kidney in a pediatric rat model
of sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 301:F209-
F217.
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR,
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S,
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
50
Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB,
Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein
BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF,
Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W and Tompkins RG
(2013) Genomic responses in mouse models poorly mimic human inflammatory
diseases. Proc Natl Acad Sci USA 110:3507-3512.
Shah BA and Padbury JF (2014) Neonatal sepsis: an old problem with new insights.
Virulence 5:170-178.
Shahul S, Gulati G, Hacker MR, Mahmood F, Canelli R, Nizamuddin J, Mahmood B,
Mueller A, Simon BA, Novack V and Talmor D (2015) Detection of Myocardial
Dysfunction in Septic Shock: A Speckle-Tracking Echocardiography Study.
Anesth Analg 121:1547-1554.
Sims CR, MacMillan-Crow LA and Mayeux PR (2014) Targeting mitochondrial oxidants
may facilitate recovery of renal function during infant sepsis. Clin Pharmacol Ther
96:662-664.
Soerensen KE, Nielsen OL, Birck MM, Soerensen DB, Leifsson PS, Jensen HE,
Aalbaek B, Kristensen AT, Wiinberg B, Kjelgaard-Hansen M, Heegaard PM and
Iburg TM (2012) The use of sequential organ failure assessment parameters in
an awake porcine model of severe Staphylococcus aureus sepsis. APMIS
120:909-921.
Souza AC, Yuen PS and Star RA (2015) Microparticles: markers and mediators of
sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney
Int 87:1100-1108.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
51
Srinivasan L, Kirpalani H and Cotten CM (2015) Elucidating the role of genomics in
neonatal sepsis. Semin Perinatol 39:611-616.
Starr ME, Steele AM, Saito M, Hacker BJ, Evers BM and Saito H (2014) A new cecal
slurry preparation protocol with improved long-term reproducibility for animal
models of sepsis. PLoS One 9:e115705.
Starr ME, Takahashi H, Okamura D, Zwischenberger BA, Mrazek AA, Ueda J,
Stromberg AJ, Evers BM, Esmon CT and Saito H (2015) Increased coagulation
and suppressed generation of activated protein C in aged mice during intra-
abdominal sepsis. Am J Physiol Heart Circ Physiol 308:H83-89H81.
Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S and Remick DG
(2011) The Pathogenesis of Sepsis. Annu Rev Pathol 6:19-48.
Stevenson EK, Rubenstein AR, Radin GT, Wiener RS and Walkey AJ (2014) Two
decades of mortality trends among patients with severe sepsis: a comparative
meta-analysis*. Crit Care Med 42:625-631.
Stubbs DJ, Yamamoto AK and Menon DK (2013) Imaging in sepsis-associated
encephalopathy--insights and opportunities. Nat Rev Neurol 9:551-561.
Suetrong B and Walley KR (2015) Lactic acidosis in sepsis: It's not all anaerobic.
Implications for diagnosis and management. Chest in press.
Sun Z, Ye H, Shen X, Chao H, Wu X and Yang J (2014) Continuous venovenous
hemofiltration versus extended daily hemofiltration in patients with septic acute
kidney injury: a retrospective cohort study. Crit Care 18:R70.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
52
Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC and Devarajan P (2003)
Differential gene expression following early renal ischemia/reperfusion. Kidney
Int 63:1714-1724.
Taccone FS, Su F, De Deyne C, Abdellhai A, Pierrakos C, He X, Donadello K, Dewitte
O, Vincent JL and De Backer D (2014) Sepsis is associated with altered cerebral
microcirculation and tissue hypoxia in experimental peritonitis. Crit Care Med
42:e114-122.
Talan DA (2015) Procalcitonin Is Not a Useful Biomarker of Sepsis. Ann Emerg Med
66:320-321.
Taylor FB, Jr., Kinasewitz GT and Lupu F (2012) Pathophysiology, staging and therapy
of severe sepsis in baboon models. J Cell Mol Med 16:672-682.
Torio CM and Andrews RM (2013) National Inpatient Hospital Costs: The Most
Expensive Conditions by Payer, 2011: Statistical Brief #160, in Healthcare Cost
and Utilization Project (HCUP) Statistical Briefs, Rockville (MD).
Tsalik EL, Willig LK, Rice BJ, van Velkinburgh JC, Mohney RP, McDunn JE, Dinwiddie
DL, Miller NA, Mayer ES, Glickman SW, Jaehne AK, Glew RH, Sopori ML, Otero
RM, Harrod KS, Cairns CB, Fowler VG, Rivers EP, Woods CW, Kingsmore SF
and Langley RJ (2015) Renal systems biology of patients with systemic
inflammatory response syndrome. Kidney Int 88:804-814.
Turnbull IR, Clark AT, Stromberg PE, Dixon DJ, Woolsey CA, Davis CG, Hotchkiss RS,
Buchman TG and Coopersmith CM (2009) Effects of aging on the
immunopathologic response to sepsis. Crit Care Med 37:1018-1023.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
53
Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT,
McDonough JS, Tschoep J, Ferguson TA, McDunn JE, Morre M, Hildeman DA,
Caldwell CC and Hotchkiss RS (2010) IL-7 promotes T cell viability, trafficking,
and functionality and improves survival in sepsis. J Immumol 184:3768-3779.
Vincent JL, Opal SM, Marshall JC and Tracey KJ (2013) Sepsis definitions: time for
change. Lancet 381:774-775.
Wacker C, Prkno A, Brunkhorst FM and Schlattmann P (2013) Procalcitonin as a
diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet
Infect Dis 13:426-435.
Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD,
Dempfle CE, Levi M, Toh CH and The Scientific Standardization Committee on
DICotISoTH (2013) Guidance for diagnosis and treatment of DIC from
harmonization of the recommendations from three guidelines. J Thromb Haemost
11:761-767.
Wald R, Adhikari NK, Smith OM, Weir MA, Pope K, Cohen A, Thorpe K, McIntyre L,
Lamontagne F, Soth M, Herridge M, Lapinsky S, Clark E, Garg AX, Hiremath S,
Klein D, Mazer CD, Richardson RM, Wilcox ME, Friedrich JO, Burns KE and
Bagshaw SM (2015) Comparison of standard and accelerated initiation of renal
replacement therapy in acute kidney injury. Kidney Int 88:897-904.
Wang B, Chen G, Zhang J, Xue J, Cao Y and Wu Y (2015a) Increased Neutrophil
Gelatinase-Associated Lipocalin is Associated with Mortality and Multiple Organ
Dysfunction Syndrome in Severe Sepsis and Septic Shock. Shock 44:234-238.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
54
Wang H and Ma S (2008) The cytokine storm and factors determining the sequence
and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J
Emerg Med 26:711-715.
Wang K, Bhandari V, Giuliano JS, Jr., CS OH, Shattuck MD and Kirby M (2014)
Angiopoietin-1, angiopoietin-2 and bicarbonate as diagnostic biomarkers in
children with severe sepsis. PLoS One 9:e108461.
Wang L and Dudek SM (2009) Regulation of vascular permeability by sphingosine 1-
phosphate. Microvasc Res 77:39-45.
Wang Z, Sims CR, Patil NK, Gokden N and Mayeux PR (2015b) Pharmacologic
targeting of sphingosine-1-phosphate receptor 1 improves the renal
microcirculation during sepsis in the mouse. J Pharmacol Exp Ther 352:61-66.
Ward NS, Casserly B and Ayala A (2008) The compensatory anti-inflammatory
response syndrome (CARS) in critically ill patients. Clin Chest Med 29:617-625.
Ward PA (2012) New approaches to the study of sepsis. EMBO Mol Med 4:1234-1243.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A,
Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M,
Bone RC, Opal SM and KyberSept Trial Study G (2001) Caring for the critically ill
patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
J Am Med Assoc 286:1869-1878.
Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A,
Singhi SC, Erickson S, Roy JA, Bush JL, Nadkarni VM, Thomas NJ, Sepsis
Prevalence O, Therapies Study I, the Pediatric Acute Lung I and Sepsis
Investigators N (2015) Global epidemiology of pediatric severe sepsis: the sepsis
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
55
prevalence, outcomes, and therapies study. Am J Respir Crit Care Med
191:1147-1157.
Wepler M, Hafner S, Scheuerle A, Reize M, Groger M, Wagner F, Simon F, Matallo J,
Gottschalch F, Seifritz A, Stahl B, Matejovic M, Kapoor A, Moller P, Calzia E,
Georgieff M, Wachter U, Vogt JA, Thiemermann C, Radermacher P and McCook
O (2013) Effects of the PPAR-beta/delta agonist GW0742 during resuscitated
porcine septic shock. Intensive Care Med Exp 1:28.
Wheeler DS, Wong HR and Zingarelli B (2011) Pediatric Sepsis - Part I: "Children are
not small adults!". Open Inflamm J 4:4-15.
Winkler MS, Nierhaus A, Holzmann M, Mudersbach E, Bauer A, Robbe L, Zahrte C,
Geffken M, Peine S, Schwedhelm E, Daum G, Kluge S and Zoellner C (2015)
Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit
Care 19:372.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL,
Fitzgerald J, Checchia PA, Meyer K, Shanley TP, Quasney M, Hall M, Gedeit R,
Freishtat RJ, Nowak J, Raj SS, Gertz S, Dawson E, Howard K, Harmon K, Lahni
P, Frank E, Hart KW and Lindsell CJ (2015a) A Multibiomarker-Based Model for
Estimating the Risk of Septic Acute Kidney Injury. Crit Care Med 43:1646-1653.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL,
Fitzgerald J, Checchia PA, Meyer K, Shanley TP, Quasney M, Hall M, Gedeit R,
Freishtat RJ, Nowak J, Shekhar RS, Gertz S, Dawson E, Howard K, Harmon K,
Beckman E, Frank E and Lindsell CJ (2015b) Developing a clinically feasible
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
56
personalized medicine approach to pediatric septic shock. Am J Respir Crit Care
Med 191:309-315.
Wong HR, Weiss SL, Giuliano JS, Jr., Wainwright MS, Cvijanovich NZ, Thomas NJ,
Allen GL, Anas N, Bigham MT, Hall M, Freishtat RJ, Sen A, Meyer K, Checchia
PA, Shanley TP, Nowak J, Quasney M, Chopra A, Fitzgerald JC, Gedeit R,
Banschbach S, Beckman E, Lahni P, Hart K and Lindsell CJ (2014) Testing the
prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS
One 9:e86242.
Wood M, Song A, Maslove D, Ferri C, Howes D, Muscedere J and Boyd JG ((in press))
Brain Tissue Oxygenation in Patients with Septic Shock: a Feasibility Study. Can
J Neurol Sci.
Wu L, Gokden N and Mayeux PR (2007) Evidence for the role of reactive nitrogen
species in polymicrobial sepsis-induced renal peritubular capillary dysfunction
and tubular injury. J Am Soc Nephrol 18:1807-1815.
Wynn JL, Scumpia PO, Delano MJ, O'Malley KA, Ungaro R, Abouhamze A and
Moldawer KL (2007) Increased mortality and altered immunity in neonatal sepsis
produced by generalized peritonitis. Shock 28:675-683.
Wynn JL, Scumpia PO, Winfield RD, Delano MJ, Kelly-Scumpia K, Barker T, Ungaro R,
Levy O and Moldawer LL (2008) Defective innate immunity predisposes murine
neonates to poor sepsis outcome but is reversed by TLR agonists. Blood
112:1750-1758.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
57
Xiao Z, Wilson C, Robertson HL, Roberts DJ, Ball CG, Jenne CN and Kirkpatrick AW
(2015) Inflammatory mediators in intra-abdominal sepsis or injury - a scoping
review. Crit Care 19:373.
Yao X, Carlson D, Sun Y, Ma L, Wolf SE, Minei JP and Zang QS (2015) Mitochondrial
ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a
Pneumonia-Related Sepsis Model. PLoS One 10:e0139416.
Yini S, Heng Z, Xin A and Xiaochun M (2015) Effect of unfractionated heparin on
endothelial glycocalyx in a septic shock model. Acta Anaesthesiol Scand 59:160-
169.
Zang QS, Sadek H, Maass DL, Martinez B, Ma L, Kilgore JA, Williams NS, Frantz DE,
Wigginton JG, Nwariaku FE, Wolf SE and Minei JP (2012) Specific inhibition of
mitochondrial oxidative stress suppresses inflammation and improves cardiac
function in a rat pneumonia-related sepsis model. Am J Physiol Heart Circ
Physiol 302:H1847-H1859.
Zanotti-Cavazzoni SL and Goldfarb RD (2009) Animal models of sepsis. Crit Care Clin
25:703-719.
Zeng Y, Adamson RH, Curry FR and Tarbell JM (2014) Sphingosine-1-phosphate
protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol
Heart Circ Physiol 306:H363-H372.
Zhao X, Chen YX and Li CS (2015) Predictive value of the complement system for
sepsis-induced disseminated intravascular coagulation in septic patients in
emergency department. J Crit Care 30:290-295.
Ziaja M (2013) Septic encephalopathy. Curr Neurol Neurosci Rep 13:383.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
58
Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, Rohwedder I,
Hinkel R, Gross L, Lee S, Hu J, Soehnlein O, Franz WM, Sperandio M, Pohl U,
Thomas M, Weber C, Augustin HG, Fassler R, Deutsch U and Kupatt C (2013)
Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J
Clin Invest 123:3436-3445.
Zonneveld R, Martinelli R, Shapiro NI, Kuijpers TW, Plotz FB and Carman CV (2014)
Soluble adhesion molecules as markers for sepsis and the potential
pathophysiological discrepancy in neonates, children and adults. Crit Care
18:204.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
59
Footnotes
This work was supported by the National Institutes of Health National Institute of
Diabetes and Digestive Kidney Diseases [F31 DK104533]; and National Institutes of
Health Institute of General Medical Sciences [R01 GM106419, GM112806]; the National
Institutes of Health National Center for Advancing Translational Sciences Clinical and
Translational Science Award [Grant UL1-TR000039].
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
JPET #230797
60
Figure Legends
Fig. 1. Conceptual framework for the use of discussed biomarkers in combination to
direct the development, validation and use of targeted therapies.
Fig. 2. Age, genetics, environmental factors, and comorbidities contribute to the
diversity of septic patients, with the young and the elderly populations being the most
susceptible to sepsis. As the systemic inflammatory response syndrome (SIRS) and
sepsis progress to severe sepsis with multiple organ dysfunction syndrome (MODS),
biomarkers could be used to guide targeted therapy that would halt the progression of
sepsis to increase survival and decrease morbidity.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
Inflammatory Biomarkers E-, L-, P-selectin ICAM-1, VCAM-1 CRP, PCT TNF-α IL-1, IL-6, IL-8, IL-27 HLA-DR PD-1 Lymphopenia Increased percentage of T
regulatory cells
Endothelial Biomarkers Syndecan-1 Heparan Sulfate Ang-1, Ang-2 Tie-2 S1P Microparticles
Coagulation Biomarkers Prothrombin Time Activated Partial
Thromboplastin Time D-dimer Platelet Count VWF Ultralarge VWF Multimers Fibrinogen ADAMTS-13
Organ-Directed and Physiological Biomarkers Brain:
Changes in EEG Cognitive Impairment Perfusion (NIRS)
Heart: Myocardial Dysfunction
(Echocardiography) Troponin
Kidney:
Perfusion (Ultrasound, MRI) Creatinine Clearance NGAL, KIM-1, NAG,
Liver:
ALT, AST Lung:
Ratio of partial pressure of O2 to fractional inspired O2
Microcirculation:
Blood Lactate Sublingual Perfusion Mixed venous O2 saturation
Tissue Injury: MMP-8, Extracellular Histones
Targeted Therapies Immunomodulation
Endothelium Microvasculature
Coagulation Organ-specific
Figure 1
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on February 8, 2016 as DOI: 10.1124/jpet.115.230797
at ASPE
T Journals on July 12, 2018
jpet.aspetjournals.orgD
ownloaded from
Definitions
Systemic Inflammatory Response Syndrome (SIRS): Two or more of the following:
• fever or hypothermia • tachycardia • tachypnea • leukocytosis or leukopenia
Sepsis: SIRS with a known infection
Severe Sepsis: Sepsis with 1 organ dysfunction or multiple organ dysfunction syndrome (MODS)
Sepsis
Severe Sepsis
SIRS
Death
Decreased Morbidity
Young (< 1 yr) Immature Immune System and Organ Development
Old (> 65 yrs) Weakened Immune System
and Comorbidities
Increased Survival
Biomarker-DirectedTherapy
Biomarker-DirectedTherapy
Biomarker-DirectedTherapy
Figure 2